![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
D Belelli, JM Balcarek, AG Hope, JA Peters, JJ Lambert and TP Blackburn
Department of Pharmacology and Clinical Pharmacology, Ninewells Hospital and Medical School, The University, Dundee, UK.
A human 5-hydroxytryptamine receptor type 3AS (5-HT3R-AS) subunit has been cloned from an amygdala cDNA library. We report the nucleotide and predicted amino acid sequence of the human subunit, which possesses 85% and 84% amino acid sequence identity with mouse and rat 5-HT3R-AS subunits, respectively. Acting on Xenopus laevis oocytes injected with RNA transcripts of the clone, 5-HT and selective 5-HT3 receptor agonists elicited inwardly directed current responses that displayed desensitization. Such currents were blocked in a concentration- dependent manner by selective and nonselective 5-HT3 receptor antagonists but were unaffected by compounds acting at G protein-linked 5-HT receptors. A quantitative comparison of the pharmacological profiles of human and mouse recombinant 5-HT3R-AS receptor complexes revealed differences in the potencies of some antagonist or agonist compounds tested, the most dramatic example being (+)-tubocurarine, which demonstrated an approximately 1800-fold discrepancy in antagonist potency. In view of the small number of sequence substitutions that occur between the human and mouse homologues of the 5-HT3R-AS in the extracellularly located aminoterminal domain, compounds such as (+)- tubocurarine, in conjunction with site-directed mutagenesis, may prove to be valuable in locating amino acid residues that contribute to the ligand binding site(s) of the 5-HT3 receptor. Also, when methodological differences are taken into account, the present study suggests that a homo-oligomeric assembly of human 5-HT3R-AS subunits can account for the distinctive ligand binding properties of human 5-HT3 receptors established in postmortem brain tissue.
This article has been cited by other articles:
|
|
 |
|
  M. R. Livesey, M. A. Cooper, T. Z. Deeb, J. E. Carland, J. Kozuska, Tim. G. Hales, J. J. Lambert, and J. A. Peters Structural Determinants of Ca2+ Permeability and Conduction in the Human 5-Hydroxytryptamine Type 3A Receptor J. Biol. Chem., July 11, 2008; 283(28): 19301 - 19313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Niesler, J. Walstab, S. Combrink, D. Moller, J. Kapeller, J. Rietdorf, H. Bonisch, M. Gothert, G. Rappold, and M. Bruss Characterization of the Novel Human Serotonin Receptor Subunits 5-HT3C,5-HT3D, and 5-HT3E Mol. Pharmacol., July 1, 2007; 72(1): 8 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Z. Deeb, J. E. Carland, M. A. Cooper, M. R. Livesey, J. J. Lambert, J. A. Peters, and T. G. Hales Dynamic Modification of a Mutant Cytoplasmic Cysteine Residue Modulates the Conductance of the Human 5-HT3A Receptor J. Biol. Chem., March 2, 2007; 282(9): 6172 - 6182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Sessoms-Sikes, M. E. Hamilton, L.-X. Liu, D. M. Lovinger, and T. K. Machu A Mutation in Transmembrane Domain II of the 5-Hydroxytryptamine3A Receptor Stabilizes Channel Opening and Alters Alcohol Modulatory Actions J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 595 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-B. Tremblay, R. Kaiser, O. Sezer, N. Rosler, C. Schelenz, K. Possinger, I. Roots, and J. Brockmoller Variations in the 5-Hydroxytryptamine Type 3B Receptor Gene as Predictors of the Efficacy of Antiemetic Treatment in Cancer Patients J. Clin. Oncol., June 1, 2003; 21(11): 2147 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, M. Hosoi, M. Fukuzawa, H. Sun, R. R. Rawlings, and F. F. Weight Distinct Molecular Basis for Differential Sensitivity of the Serotonin Type 3A Receptor to Ethanol in the Absence and Presence of Agonist J. Biol. Chem., November 22, 2002; 277(48): 46256 - 46264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Morales and S.-D. Wang Differential Composition of 5-Hydroxytryptamine3 Receptors Synthesized in the Rat CNS and Peripheral Nervous System J. Neurosci., August 1, 2002; 22(15): 6732 - 6741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Machu, M. E. Hamilton, T. F. Frye, C. L. Shanklin, M. C. Harris, H. Sun, T. E. Tenner Jr., F. S. Soti, and W. R. Kem Benzylidene Analogs of Anabaseine Display Partial Agonist and Antagonist Properties at the Mouse 5-Hydroxytryptamine3A Receptor J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1112 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Steward, F. G. Boess, J. A. Steele, D. Liu, N. Wong, and I. L. Martin Importance of Phenylalanine 107 in Agonist Recognition by the 5-Hydroxytryptamine3A Receptor Mol. Pharmacol., June 1, 2000; 57(6): 1249 - 1255. [Abstract] [Full Text]
|
|
|
|
|
|
A. D. Spier and S. C. R. Lummis The Role of Tryptophan Residues in the 5-Hydroxytryptamine3 Receptor Ligand Binding Domain J. Biol. Chem., February 25, 2000; 275(8): 5620 - 5625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Dubin, R. Huvar, M. R. D'Andrea, J. Pyati, J. Y. Zhu, K. C. Joy, S. J. Wilson, J. E. Galindo, C. A. Glass, L. Luo, et al. The Pharmacological and Functional Characteristics of the Serotonin 5-HT3A Receptor Are Specifically Modified by a 5-HT3B Receptor Subunit J. Biol. Chem., October 22, 1999; 274(43): 30799 - 30810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Hope, D. Belelli, I. D. Mair, J. J. Lambert, and J. A. Peters Molecular Determinants of (+)-Tubocurarine Binding at Recombinant 5-Hydroxytryptamine3A Receptor Subunits Mol. Pharmacol., June 1, 1999; 55(6): 1037 - 1043. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. A. van Hooft, A. D. Spier, J. L. Yakel, S. C. R. Lummis, and H. P. M. Vijverberg Promiscuous coassembly of serotonin 5-HT3 and nicotinic alpha 4 receptor subunits into Ca2+-permeable ion channels PNAS, September 15, 1998; 95(19): 11456 - 11461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Giovannini, I. Ceccarelli, B. Molinari, M. Cecchi, J. Goldfarb, and P. Blandina Serotonergic Modulation of Acetylcholine Release from Cortex of Freely Moving Rats J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1219 - 1225. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
